Alto Neuroscience is a provider of mental health treatment drugs, mainly engaged in the research and application of AI to predict antidepressants, and to measure the condition by analyzing patients’ EEG activity, behavioral performance and health data. Products are suitable for depression, trauma Post-stress disorder and other mental health conditions. Alto Neuroscience raises $35 million in Series B funding. The round was led by Lightswitch Capital and Alkeon Capital, with participation from Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, Gangels, Apeiron Group, WhatIf Venture and Windham Venture Partners. Christopher Cox, CEO of Lightswitch Capital, and Dr. Jeff Chen, Managing Director of Alkeon Capital, join Alto’s Board of Directors. In addition, Bob Baloh, MD, Global Head of Neuroscience at the Novartis Institutes for Biomedical Research (NIBR), will join as a board observer.
This article is reproduced from: https://www.itjuzi.com/investevent/13625667
This site is for inclusion only, and the copyright belongs to the original author.